Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era.

Br J Surg · 2018 · PMC6033139 · PMID 29664995

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The BRF14 trial of the French Sarcoma Group 32 , which solely included patients with metastatic disease who were started on imatinib, showed a highly significant 5‐year survival benefit for women of 76·5 per cent, versus 53·5 per cent in men.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.